153 related articles for article (PubMed ID: 26069962)
1. Seneca Valley Virus 3Cpro Substrate Optimization Yields Efficient Substrates for Use in Peptide-Prodrug Therapy.
Miles LA; Brennen WN; Rudin CM; Poirier JT
PLoS One; 2015; 10(6):e0129103. PubMed ID: 26069962
[TBL] [Abstract][Full Text] [Related]
2. Seneca Valley Virus Suppresses Host Type I Interferon Production by Targeting Adaptor Proteins MAVS, TRIF, and TANK for Cleavage.
Qian S; Fan W; Liu T; Wu M; Zhang H; Cui X; Zhou Y; Hu J; Wei S; Chen H; Li X; Qian P
J Virol; 2017 Aug; 91(16):. PubMed ID: 28566380
[TBL] [Abstract][Full Text] [Related]
3. [Current research on picornavirus 3C protease].
Wang H; Xie GC; Duan ZJ
Bing Du Xue Bao; 2014 Sep; 30(5):579-86. PubMed ID: 25562970
[TBL] [Abstract][Full Text] [Related]
4. Seneca Valley Virus 3C
Xue Q; Liu H; Zhu Z; Xue Z; Liu X; Zheng H
Pathogens; 2020 Jun; 9(6):. PubMed ID: 32512928
[TBL] [Abstract][Full Text] [Related]
5. Seneca Valley Virus 3C protease negatively regulates the type I interferon pathway by acting as a viral deubiquitinase.
Xue Q; Liu H; Zhu Z; Yang F; Xue Q; Cai X; Liu X; Zheng H
Antiviral Res; 2018 Dec; 160():183-189. PubMed ID: 30408499
[TBL] [Abstract][Full Text] [Related]
6. Allosteric regulation of Senecavirus A 3Cpro proteolytic activity by an endogenous phospholipid.
Zhao HF; Meng L; Geng Z; Gao ZQ; Dong YH; Wang HW; Zhang H
PLoS Pathog; 2023 May; 19(5):e1011411. PubMed ID: 37253057
[TBL] [Abstract][Full Text] [Related]
7. Efficient and rapid affinity purification of proteins using recombinant fusion proteases.
Walker PA; Leong LE; Ng PW; Tan SH; Waller S; Murphy D; Porter AG
Biotechnology (N Y); 1994 Jun; 12(6):601-5. PubMed ID: 7764949
[TBL] [Abstract][Full Text] [Related]
8. Seneca Valley Virus Induces DHX30 Cleavage to Antagonize Its Antiviral Effects.
Wen W; Zheng Z; Wang H; Zhao Q; Yin M; Chen H; Li X; Qian P
J Virol; 2022 Sep; 96(17):e0112122. PubMed ID: 36000840
[TBL] [Abstract][Full Text] [Related]
9. Seneca Valley Virus 2C and 3C
Liu T; Li X; Wu M; Qin L; Chen H; Qian P
Front Microbiol; 2019; 10():1202. PubMed ID: 31191506
[TBL] [Abstract][Full Text] [Related]
10. Seneca Valley Virus 3C
Song J; Quan R; Wang D; Liu J
Microbiol Spectr; 2022 Apr; 10(2):e0030422. PubMed ID: 35357201
[TBL] [Abstract][Full Text] [Related]
11. Characterization of a full-length infectious cDNA clone and a GFP reporter derivative of the oncolytic picornavirus SVV-001.
Poirier JT; Reddy PS; Idamakanti N; Li SS; Stump KL; Burroughs KD; Hallenbeck PL; Rudin CM
J Gen Virol; 2012 Dec; 93(Pt 12):2606-2613. PubMed ID: 22971818
[TBL] [Abstract][Full Text] [Related]
12. Specificity of the polioviral proteinase 3C towards genetically engineered cleavage sites in the viral capsid.
Mirzayan C; Ingraham R; Wimmer E
J Gen Virol; 1991 May; 72 ( Pt 5)():1159-63. PubMed ID: 1851816
[TBL] [Abstract][Full Text] [Related]
13. Seneca valley virus 3C protease blocks EphA2-Mediated mTOR activation to facilitate viral replication.
Shi Y; Wu Z; Zeng P; Song J; Guo J; Yang X; Zhou J; Liu J; Hou L
Microb Pathog; 2024 Jun; 191():106673. PubMed ID: 38705218
[TBL] [Abstract][Full Text] [Related]
14. Correction: Seneca Valley Virus 3Cpro Substrate Optimization Yields Efficient Substrates for use in Peptide-Prodrug Therapy.
Miles LA; Brennen WN; Rudin CM; Poirier JT
PLoS One; 2015; 10(8):e0136480. PubMed ID: 26287921
[No Abstract] [Full Text] [Related]
15. Structure of Seneca Valley Virus-001: an oncolytic picornavirus representing a new genus.
Venkataraman S; Reddy SP; Loo J; Idamakanti N; Hallenbeck PL; Reddy VS
Structure; 2008 Oct; 16(10):1555-61. PubMed ID: 18940610
[TBL] [Abstract][Full Text] [Related]
16. Structural basis for anthrax toxin receptor 1 recognition by Seneca Valley Virus.
Jayawardena N; Burga LN; Easingwood RA; Takizawa Y; Wolf M; Bostina M
Proc Natl Acad Sci U S A; 2018 Nov; 115(46):E10934-E10940. PubMed ID: 30381454
[TBL] [Abstract][Full Text] [Related]
17. A Structure-Guided Genetic Modification Strategy: Developing Seneca Valley Virus Therapy against Nonsensitive Nonsmall Cell Lung Carcinoma.
Zhao Z; Cao L; Sun Z; Liu W; Li X; Fang K; Shang X; Hu J; Chen H; Lou Z; Qian P
J Virol; 2023 May; 97(5):e0045923. PubMed ID: 37097154
[TBL] [Abstract][Full Text] [Related]
18. Development of in vitro peptide substrates for human rhinovirus-14 2A protease.
Wang QM; Johnson RB; Sommergruber W; Shepherd TA
Arch Biochem Biophys; 1998 Aug; 356(1):12-8. PubMed ID: 9681985
[TBL] [Abstract][Full Text] [Related]
19. Human rhinovirus-14 protease 3C (3Cpro) binds specifically to the 5'-noncoding region of the viral RNA. Evidence that 3Cpro has different domains for the RNA binding and proteolytic activities.
Leong LE; Walker PA; Porter AG
J Biol Chem; 1993 Dec; 268(34):25735-9. PubMed ID: 8245010
[TBL] [Abstract][Full Text] [Related]
20. Recent development of 3C and 3CL protease inhibitors for anti-coronavirus and anti-picornavirus drug discovery.
Ramajayam R; Tan KP; Liang PH
Biochem Soc Trans; 2011 Oct; 39(5):1371-5. PubMed ID: 21936817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
